Lifestyle
- Regular health check-ups
- Avoid exposure to copper-containing pesticides
- Monitor liver health
Copper · Serum Copper · Cu
The test quantifies the concentration of copper in the serum, reflecting copper status in the body.
Reference ranges may vary slightly based on laboratory standards.
Copper (Cu) is a trace element that plays a crucial role in various biological processes, including iron metabolism, antioxidant defense, and neurotransmitter synthesis. It is primarily measured in serum to assess copper status in the body. Researchers have found that copper is essential for the function of several enzymes, such as cytochrome c oxidase and superoxide dismutase, which are vital for cellular respiration and protection against oxidative stress. Clinically, serum copper levels are important in diagnosing and monitoring conditions like Wilson's disease, a genetic disorder characterized by copper accumulation in tissues leading to hepatic and neurological symptoms. Elevated copper levels can also indicate other disorders such as Menkes disease and certain toxicities. In the context of athletic performance and biohacking, maintaining optimal copper levels is crucial for energy production and antioxidant defense, which can enhance endurance and recovery. However, researchers observed that copper levels can be influenced by various factors, including dietary intake, genetic disorders, and liver function. Time of day and fasting status are not significant confounders, but it is essential to consider potential interference from supplements or medications that affect copper metabolism.
Klinische Bedeutung
Elevated serum copper levels may indicate Wilson's disease, liver disease, or copper toxicity. Reduced levels can suggest Menkes disease or malnutrition.
Progressively rising values may suggest worsening of copper overload conditions like Wilson's disease. Retest every 4 weeks if outside optimal range.
Progressively falling values could indicate effective treatment of copper overload or onset of deficiency.
Re-test Interval
4 weeks if outside optimal range
Note:
Consult a healthcare provider before starting any supplementation, especially if you have a genetic disorder affecting copper metabolism.
Testing Frequency
Annually for individuals with risk factors, more frequently if managing a condition like Wilson's disease
Correlated with
Current research suggests that reference ranges for serum ceruloplasmin and urinary copper excretion in diagnosing Wilson's disease remain debated, particularly regarding their sensitivity and specificity. Researchers have not yet established optimal targets for managing copper levels in patients, especially concerning the role of non-ceruloplasmin-bound copper. Additionally, unanswered clinical questions include the effectiveness of novel therapeutic approaches in preventing neurological deterioration and the potential for incorporating new diagnostic assays into routine screening.
427
Total Citations
10
Human/RCT
2.1
Avg. Influence
2025
Latest
Researchers found that relative exchangeable copper (REC) and exchangeable copper (CuEXC) are reliable biomarkers for diagnosing Wilson's disease. These tests provide rapid, non-invasive assessments of copper overload, facilitating early diagnosis and treatment without waiting for genetic test results.
Researchers discussed the challenges of diagnosing Wilson's disease, noting its nonspecific neurological symptoms. They found that laboratory abnormalities related to copper homeostasis are crucial for diagnosis, and timely treatment can prevent severe outcomes. The study also highlighted the importance of lifelong pharmacologic management.
Researchers found that patients with depressive disorder had higher blood levels of copper compared to controls, suggesting a potential link between copper levels and mental health. The study conducted a meta-analysis of 21 studies, indicating that increased blood copper might be associated with depression, although hair copper levels showed no difference.
Researchers examined the interactions between zinc, copper, and lead, noting that zinc deficiency can lead to copper overload. They proposed using zinc therapy to manage copper levels in Wilson's disease, highlighting the importance of trace element interactions in clinical settings.
Researchers found that altered copper metabolism may serve as a new biomarker for hepatocellular carcinoma (HCC) detection. Increased copper accumulation was observed in HCC tissues, and copper-64 chloride showed potential in molecular imaging for HCC metastasis. The study suggests that targeting copper metabolism could enhance imaging and therapy for HCC.
Researchers conducted a systematic review on ATP7A-related copper transport disorders to identify clinical subtypes and management guidelines. They found that low ceruloplasmin is a sensitive biomarker for these disorders, outperforming serum copper levels. The study emphasized the need for clear clinical criteria to differentiate between subtypes.
This study examined the relationship between serum copper levels and cardiovascular disease (CVD) mortality in Finnish men. Researchers found that higher serum copper levels were associated with an increased risk of CVD death across different body mass index categories.
This paper reviewed the biochemical tests used to diagnose Wilson's disease, noting the limitations of current methods. Researchers found that serum ceruloplasmin and urinary copper excretion are key diagnostic indicators, while relative exchangeable copper shows high sensitivity and specificity.
Researchers evaluated the diagnostic performance of different copper biomarkers in Wilson's disease. They found that relative exchangeable copper significantly differentiates patients with Wilson's disease from other liver conditions. The study suggests including this biomarker in future diagnostic criteria.
Researchers found that zinc-induced copper deficiency is often overlooked, with 50% of diagnosed cases previously undetected. The study emphasizes the need for better monitoring of serum zinc and copper levels in patients prescribed zinc to prevent this rare but significant condition.
9
Total Trials
836
Total Enrolled
University Hospital Southampton NHS Foundation Trust
180
2024
Phase 1: Accuracy of the Preemie system against reference laboratory International Standards Organization (ISO) methods.
Postgraduate Institute of Dental Sciences Rohtak
30
2024
ARCH ALIGNMENT
Nanfang Hospital, Southern Medical University
10
2023
Objective response rate (ORR)
Institute of Oncology Ljubljana
20
2023
Serum copper (Cu) as a predictive biomarker of the response to systemic treatment of biliary tract cancer patients
Assiut University
60
2019
The mean difference of syndecan 4 expression and substance P before and after treatment
The Institute of Molecular and Translational Medicine, Czech Republic
9
2017
Clinical response rate (RR)
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
20
2016
Feasibility of Cu-64-TP3805 to detect UC as determined by post-surgical histology
Alexandria University
107
2015
Evaluation of zinc to copper ratio as biomarker of micro-nutrient deficiency
Regional Cardiology Center, The Copper Health Centre (MCZ),
400
2013
Target lesion failure (TLF)
Research publications about Kupfer over time
9totalLog lab results, track trends and optimize your biomarkers over time.
This page is for informational and research purposes only. All information is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. Many substances listed may not be approved for human use and may be subject to drug regulation laws (e.g., AMG in Germany, FDA in the US). PepStack does not encourage the use of any substance on humans. Always consult a qualified healthcare professional before making any health-related decisions. Use of this information is entirely at your own risk. PepStack assumes no liability for the accuracy, completeness, or timeliness of the content provided. Full disclaimer